10-K: Xeris Biopharma Holdings, Inc. Files 10-K Report, Highlights Growth and Financial Strategies

Xeris Biopharma's 2023 10-K filing details the company's financial performance, strategic initiatives, and risk factors, emphasizing its focus on commercial growth and innovative product development.

Summary

• Xeris Biopharma's 10-K filing for 2023 outlines the company's financial status, strategic goals, and potential risks.
• The company is focused on maximizing its three commercial products: Gvoke for severe hypoglycemia, Recorlev for Cushing's syndrome, and Keveyis for Primary Periodic Paralysis.
• Xeris is leveraging its proprietary formulation technologies, XeriSol and XeriJect, to develop new product candidates and enhance existing formulations.
• The company is pursuing collaborations with other pharmaceutical companies to apply its formulation science to their products.
• Xeris reported a net loss of $62.3 million for 2023, an improvement from the $94.7 million loss in 2022 and $122.7 million in 2021.
• The company's accumulated deficit as of December 31, 2023, was $617.0 million.
• Gvoke captured over 30% of the glucagon rescue retail market, generating approximately a quarter million prescriptions since launch.
• The estimated total addressable market for Gvoke is approximately $5.0 billion in the United States.
• The estimated total addressable market for Recorlev is approximately $3.0 billion in the United States.
• The estimated total addressable market for Keveyis is greater than $0.5 billion in the United States.
• Xeris is developing XP-8121, a once-weekly subcutaneous injection of levothyroxine, with a potential market opportunity of $2.0 to $3.0 billion annually.
• The company has 170 patents issued globally, including patents covering its ready-to-use glucagon formulation expiring in 2036 and patents covering Recorlev through 2040.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While there are positive signs of revenue growth and strategic initiatives, the company's ongoing losses, reliance on external funding, and competitive risks temper the overall sentiment. The company is making progress but faces significant challenges.

Positives

• Xeris has three commercial products addressing significant unmet medical needs.
• The company's proprietary formulation technologies provide a competitive advantage.
• Xeris is actively expanding its market presence and revenue through effective commercial execution.
• The company is developing a promising pipeline product, XP-8121, with a large market opportunity.
• Xeris has a strong intellectual property portfolio with patents extending to 2040.

Negatives

• Xeris has a limited operating history and has incurred significant losses since inception.
• The company may require additional capital to sustain its business, which could cause dilution to stockholders.
• Xeris faces intense competition from other pharmaceutical and biotechnology companies.
• The company relies on third-party suppliers, including single-source suppliers, which could disrupt its supply chain.
• Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance.

Risks

• Xeris may never be profitable or be able to sustain revenues.
• The company may require additional capital, which may not be available on favorable terms.
• The commercial success of Xeris' products depends on market acceptance and reimbursement.
• Xeris operates in a competitive business environment, which may negatively impact revenue.
• Reliance on third-party suppliers, including single-source suppliers, could harm the company's ability to commercialize products.
• Clinical trials may fail to demonstrate efficacy and safety, delaying or preventing marketing approval.
• Products may have undesirable side effects, limiting sales or requiring them to be taken off the market.
• The company's stock price has been and will likely continue to be volatile.

Future Outlook

Xeris expects to continue to incur significant expenses, operating losses, and net losses as it continues the commercialization of Gvoke, Recorlev, and Keveyis, develops new products, and operates as a public company. The company anticipates needing additional capital to complete clinical trials and commercialization efforts.

Management Comments

• The company is focused on maximizing the potential of its three commercial products.
• Xeris is leveraging its proprietary formulation science to develop new product candidates.
• The company is pursuing collaborations to enhance the formulations of other companies' products.

Industry Context

The biopharmaceutical industry is characterized by intense competition and rapid technological change. Xeris faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies. The company's success depends on its ability to develop and commercialize differentiated and innovative products that meet unmet medical needs.

Comparison to Industry Standards

• Xeris's revenue growth in 2023, particularly for Recorlev, indicates a strong market response to its products, which is a positive sign compared to industry averages for new drug launches.
• The company's focus on proprietary formulation technologies aligns with the industry trend towards innovative drug delivery systems, similar to companies like Alkermes and Catalent.
• The company's reliance on third-party manufacturers is a common practice in the industry, but the risk of single-source suppliers is a concern, similar to issues faced by other companies like Emergent BioSolutions.
• Xeris's R&D spending is consistent with other companies in the clinical stage, but the need for additional capital raises is a common challenge in the sector, similar to companies like BioMarin and Sarepta Therapeutics.
• The company's intellectual property portfolio, with patents extending to 2040, is a significant asset, comparable to companies like AbbVie and Gilead Sciences that rely heavily on patent protection.

Stakeholder Impact

• Shareholders may experience dilution from future capital raises.
• Employees may benefit from the company's growth and development opportunities.
• Patients may benefit from the company's innovative products addressing unmet medical needs.
• Customers may benefit from the company's products and services.
• Suppliers may benefit from the company's ongoing operations and partnerships.
• Creditors may be impacted by the company's debt obligations and financial performance.

Next Steps

• Continue to drive revenue growth through effective commercial execution of Gvoke, Recorlev, and Keveyis.
• Continue to leverage proprietary formulation science to develop internal new product candidates, particularly XP-8121.
• Collaborate with pharmaceutical and biotechnology companies to enhance their products using XeriSol and XeriJect.
• Complete the Phase 2 study for XP-8121 in the first half of 2024.

Key Dates

Keywords

Xeris Biopharma, Gvoke, Recorlev, Keveyis, XP-8121, hypoglycemia, Cushing's syndrome, Primary Periodic Paralysis, levothyroxine, XeriSol, XeriJect, biopharmaceutical, formulation science, intellectual property, clinical trials